Company Description
ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines.
The company’s products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).
It also develops various other early-stage research programs, including AX-1005 for undisclosed targets in CVDs; AX-2402, which focuses on Rett syndrome; AX-2911 for metabolic dysfunction-associated steatohepatitis (MASH) targeting patatin-like phospholipase domain-containing protein 3 (PNPLA3); AX-0601 for obesity and Type 2 diabetes; and AX-9115 for rare metabolic condition, as well as additional programs in Rett Syndrome, additional CNS programs, and multiple other unnamed targets and programs.
In addition, the company develops Axiomer RNA base-editing platform technology. It has a license agreement with Radboud University Medical Center; Inserm Transfert SA; Ionis Pharmaceuticals, Inc.; Vico Therapeutics B.V.; University of Rochester; and Leiden University Medical Center, as well as license and research collaboration with Eli Lilly and Company for the discovery, development, and commercialization of potential new medicines for genetic disorders in the liver and nervous system.
The company was incorporated in 2012 and is headquartered in Leiden, the Netherlands.
| Country | Netherlands |
| Founded | 2012 |
| IPO Date | Sep 18, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 166 |
| CEO | Daniel de Boer |
Contact Details
Address: Zernikedreef 9 Leiden, 2333 CK Netherlands | |
| Phone | 31 88 166 7000 |
| Website | proqr.com |
Stock Details
| Ticker Symbol | PRQR |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| CIK Code | 0001612940 |
| CUSIP Number | N71542109 |
| ISIN Number | NL0010872495 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Daniel Anton de Boer | Founder, Chief Executive Officer and Member of Management Board |
| Dr. Gerard Platenburg Ph.D. | Co-Founder, Chief Scientific Officer and Member of Management Board |
| Dr. Domenico Valerio Ph.D. | Founder and Independent Member of Supervisory Board |
| Rene K. Beukema | Chief Corporate Development Officer, General Counsel and Member of Management Board |
| Jurriaan Dekkers | Chief Financial Officer |
| Sheila Sponselee | Chief People and Operations Officer |
| Sarah Cue Kiely | Vice President of Investor Relations and Corporate Communications |
| Sandra van der Kolk | Junior Financial Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 14, 2025 | 6-K | Report of foreign issuer |
| Mar 25, 2025 | EFFECT | Notice of Effectiveness |
| Mar 25, 2025 | 424B5 | Filing |
| Mar 13, 2025 | S-8 | Securities to be offered to employees in employee benefit plans |
| Mar 13, 2025 | F-3 | Filing |
| Mar 13, 2025 | 20-F | Annual and transition report of foreign private issuers |
| Mar 13, 2025 | 6-K | Report of foreign issuer |
| Feb 14, 2025 | SCHEDULE 13G/A | Filing |
| Feb 12, 2025 | SCHEDULE 13G | Filing |
| Dec 12, 2024 | 6-K/A | Filing |